• Explore /
  • Poster
  • / Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Abstract Poster

Authors

null

Martin JS Dyer

The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Martin JS Dyer , Sven De Vos , Jia Ruan , Christopher Flowers , Kami J. Maddocks , Simon Rule , Ahmed M. Hamdy , Raquel Izumi , J. Greg Slatter , Jean Cheung , Melanie M. Frigualt , Helen Wei , Sanchita Mourya , Naomi N. H. Hunder , Nathan Hale Fowler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02112526

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7547)

DOI

10.1200/JCO.2018.36.15_suppl.7547

Abstract #

7547

Poster Bd #

184

Abstract Disclosures

Similar Posters

First Author: Thomas E. Witzig

Poster

2018 ASCO Annual Meeting

Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).

Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).

First Author: Nathan Hale Fowler

First Author: Thomas Lillie

First Author: L Elizabeth Budde